{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-056122","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.510916+00:00","generated_at":"2026-05-24T14:38:29.615514+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Prime Medicine unveils preclinical AATD program with up to 72% gene correction, IND/CTA expected mid-2026","bullets":["AATD program targets E342K (Pi*Z) mutation in SERPINA1 gene using LNP-delivered Prime Editors.","In humanized mice, up to 72% precise correction of SERPINA1 in hepatocytes, restoring >95% serum AAT to corrected isoform.","Serum M-AAT levels well above 20µM, indicating restoration to normal levels in mouse model.","Company expects to file IND and/or CTA for AATD program in mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-056122","json":"https://secwatch.observer/filing/0001193125-25-056122.json","markdown":"https://secwatch.observer/filing/0001193125-25-056122.md","text":"https://secwatch.observer/filing/0001193125-25-056122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000119312525056122/0001193125-25-056122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000119312525056122/d908678d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T14:38:29.615514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}